A trial of the chemotherapy drugs capecitabine and vinflunine for advanced breast cancer

Cancer type:

Breast cancer

Secondary cancers

Status:

Results

Phase:

Phase 3

This trial looked at capecitabine with or without vinflunine for breast cancer that had come back after other treatment.

The trial was open for people to join between 2009 and 2011. The team published the results in 2018.

More about this trial

Doctors usually treat breast cancer with surgery, and other treatments including chemotherapy, radiotherapy, hormone therapy or targeted cancer treatments.

But sometimes the cancer comes back or spreads to another part of the body. This is advanced, metastatic or secondary breast cancer.

Doctors sometimes treat advanced breast cancer with more chemotherapy. One of the drugs they use is capecitabine. Researchers wanted to find out if it was useful to also have another chemotherapy drug called vinflunine.

The people in this trial were put into 1 of 2 treatment groups at random:

half had capecitabine alone
half had capecitabine and vinflunine

The main aims of the trial were to find out:

if capecitabine and vinflunine works better than capecitabine alone for advanced breast cancer
how each treatment affects quality of life

Summary of results

As part of our editorial policy, any trial information we write is checked externally before we put it on our website. The research team have published some results for this trial. But we have been unable to find anyone involved with the trial to check the summary for us.

This means we are not able to include a plain English summary of the results on this page.

More information
There is more information about this trial in the link to the medical journal below.

Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.

Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane
M Martin and others
Annals of Oncology, 2018. Volume 29, issue 5, pages 1195 – 1202.